At 7.3% CAGR, the Europe Structural Heart Market is Projected to be Worth US$ 4,909.25 million by 2028, says Business Market Insights

According to Business Market Insights research, the Europe structural heart market was valued at US$ 3,213.80 million in 2022 and is expected to reach US$ 4,909.25 million by 2028, registering a CAGR of 7.3% from 2022 to 2028. Availability of innovative structural heart services and rise in the number of cardiovascular diseases and training programs are the factors attributed to the Europe structural heart market expansion.        

According to the World Health Organization (WHO), cardiovascular diseases are the second leading cause of death Europe. Therefore, various initiatives are being taken to control cardiovascular diseases. Heart valve disease is expected to be one of the most common causes of heart failure. Degenerative diseases of aortic and mitral valves, and diseases of dysfunctional tricuspid valves lead to a worse clinical course in severe cases. Minimally invasive, surgical, and catheter-based interventions for structural heart disease have increased dramatically recently. The UK Factsheet January 2022, published by the British Heart Foundation (BHF), shows that ~7.6 million people with cardiovascular diseases live in the UK. According to the same source, ~4 million men and ~3.6 million women were diagnosed with heart and circulatory diseases in the country in 2021. Owing to the high incidence of cardiovascular disease, there is a high demand for treatment procedures such as angioplasty and cardiac surgery for survival, which creates opportunities for companies providing structural heart valves and annuloplasty rings, among other devices. The structural heart is an evolving field consisting of heart valve surgeries and transcatheter procedures; therefore, various training programs are being arranged for cardiac surgeons and physicians. Over the past decade, the burgeoning incidence of structural heart disease has necessitated the development of formal training programs to ensure the appropriate competency of workforces. The structure, length, and scope of training vary greatly between programs. Most programs provide solid exposure on transcatheter aortic valve replacement (TAVR) procedures, simultaneously providing a lesser and variable experience of atrial septal or ventricular septal defect closure, left atrial appendage closure, and congenital heart defect interventions. With the advent of TAVR, the MitraClip mitral valve repair system (Abbott Vascular), and left atrial appendage occlusion (LAAO) procedures, there has been a significant increase in the volume of structural cardiac procedures performed for treating patients with complex cardiovascular conditions. Many organizations have developed services and procedural offerings in an organized format for the structural cardiac program to accommodate the influx of patients. Training in SHD is exciting, challenging, and rewarding overall. As the field evolves, standardization of SHD training becomes extremely important to ensure the best quality of patient care. Finding a mentor to help navigate the numerous considerations outlined can be the best asset to successfully transitioning from training to practice. Therefore, the burgeoning number of cardiovascular disease cases and training programs on structural heart boost the structural heart market.

On the contrary, high cost of procedures systems hampers the Europe structural heart market.  

Based on product, the Europe structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held 40.4% share of Europe structural heart market in 2022, amassing US$ 1,297.87 million. It is projected to garner US$ 2,010.28 million by 2028 to expand at 7.6% CAGR during 2022–2028. 

Based on procedure, the Europe structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. The heart valve stenosis segment held 43.7% share of Europe structural heart market in 2022, amassing US$ 1,403.76 million. It is projected to garner US$ 2,203.68 million by 2028 to expand at 7.8% CAGR during 2022–2028.

Based on end user, the Europe structural heart market is segmented into hospitals, ambulatory surgical centers, and cardiac centers. The hospitals held 47.6% share of Europe structural heart market in 2022, amassing US$ 1,531.34 million. It is projected to garner US$ 2,394.13 million by 2028 to expand at 7.1% CAGR during 2022–2028.

Based on country, the Europe structural heart market has been categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.9% share of Europe structural heart market in 2022. It was assessed at US$ 959.32 million in 2022 and is likely to hit US$ 1,531.68 million by 2028, exhibiting a CAGR of 8.1% during the 2022–2028.      

Key players operating in the Europe structural heart market are Abbott Laboratories; Medtronic Plc; Boston Scientific Corp; Artivion Inc; Edwards Lifesciences Corp; Lepu Medical Technology Beijing Co Ltd; Braile Biomedical Industry, Commerce and Representations; and Micro Interventional Devices Inc, among others.  

• During 2020–2023, various companies have adopted organic growth strategies in structural heart market. Some of the activities that have helped the companies promote their growth are launches, enhancements, expansion, relocation activities. Medtronic, Boston Scientific Corp, Lepu Medical Technology (Beijing) Co Ltd, Artinian, CORCYM, and Abbott Laboratories are among the companies that have been implementing organic strategies, which, in turn, have brought about various changes in the health economics and outcomes research services market.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com